Defining tumor antigens: mRNA, protein or cytotoxicity?
- PMID: 12102740
- DOI: 10.1016/s1471-4906(02)02196-8
Defining tumor antigens: mRNA, protein or cytotoxicity?
Comment on
-
From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens.Trends Immunol. 2001 Sep;22(9):516-23. doi: 10.1016/s1471-4906(01)02015-4. Trends Immunol. 2001. PMID: 11525943 Review.
Similar articles
-
Oncogene products represent potential targets of tumor vaccines.Cancer Immunol Immunother. 1996 Nov;43(3):135-41. doi: 10.1007/s002620050314. Cancer Immunol Immunother. 1996. PMID: 9001566 Review. No abstract available.
-
Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?Expert Opin Biol Ther. 2010 Nov;10(11):1539-53. doi: 10.1517/14712598.2010.526105. Expert Opin Biol Ther. 2010. PMID: 20955111 Review.
-
Protein tumor antigens.Curr Opin Immunol. 1991 Oct;3(5):654-8. doi: 10.1016/0952-7915(91)90092-f. Curr Opin Immunol. 1991. PMID: 1755984 Review.
-
[RNA-loaded dendritic cells].Nihon Rinsho. 2005 Apr;63 Suppl 4:613-8. Nihon Rinsho. 2005. PMID: 15861719 Review. Japanese. No abstract available.
-
Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.Tumour Biol. 2017 Jul;39(7):1010428317701309. doi: 10.1177/1010428317701309. Tumour Biol. 2017. PMID: 28677424
Cited by
-
Cancer immunotherapy: avoiding the road to perdition.J Transl Med. 2004 Jul 29;2(1):26. doi: 10.1186/1479-5876-2-26. J Transl Med. 2004. PMID: 15283862 Free PMC article.
-
Sperm protein 17 is expressed in human nervous system tumours.BMC Cancer. 2006 Jan 26;6:23. doi: 10.1186/1471-2407-6-23. BMC Cancer. 2006. PMID: 16438728 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources